Madrigal Pharmaceuticals (MDGL) Insider Trading & Ownership $440.75 +23.32 (+5.59%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$431.50 -9.25 (-2.10%) As of 09/18/2025 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Madrigal Pharmaceuticals (NASDAQ:MDGL) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage21.50%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$61.92MNumber OfInsiders Selling(Last 12 Months)10Amount OfInsider Selling(Last 12 Months)$128.70M Get MDGL Insider Trade Alerts Want to know when executives and insiders are buying or selling Madrigal Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MDGL Insider Buying and Selling by Quarter Madrigal Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/9/2025William John SiboldCEOSell7,279$445.63$3,243,740.77 8/21/2025William John SiboldCEOSell7,616$400.18$3,047,770.88 8/20/2025Bros. Advisors Lp BakerDirectorBuy59,901$385.16$23,071,469.16 8/18/2025Bros. Advisors Lp BakerDirectorBuy68,618$364.04$24,979,696.72 8/18/2025Bros. Advisors Lp BakerDirectorBuy37,164$373.21$13,869,976.44 8/18/2025Shannon T KelleyGeneral CounselSell1,304$367.81$479,624.24 8/15/2025Kenneth BateDirectorSell10,000$365.20$3,652,000.00 8/13/2025Paul A FriedmanDirectorSell129,172$370.24$47,824,641.28 8/12/2025Paul A FriedmanDirectorSell43,605$355.68$15,509,426.40 8/12/2025Rebecca TaubDirectorSell43,263$355.69$15,388,216.47 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 8/11/2025Paul A FriedmanDirectorSell3,203$350.27$1,121,914.81 8/11/2025Rebecca TaubDirectorSell3,200$350.24$1,120,768.00 7/18/2025Paul A FriedmanDirectorSell1,400$350.03$490,042.00 7/18/2025Rebecca TaubDirectorSell1,000$350.00$350,000.00 7/17/2025Paul A FriedmanDirectorSell2,700$350.48$946,296.00 7/17/2025Rebecca TaubDirectorSell2,657$350.41$931,039.37 7/16/2025Paul A FriedmanDirectorSell26,176$353.47$9,252,430.72 7/16/2025Rebecca TaubDirectorSell26,444$353.47$9,347,160.68 3/5/2025Robert E WaltermireVPSell14,113$341.32$4,817,049.16 2/28/2025Robert E WaltermireVPSell1,227$341.07$418,492.89 2/27/2025James M DalyDirectorSell15,470$347.45$5,375,051.50 1/24/2025Carole HuntsmanInsiderSell347$335.24$116,328.28 1/24/2025Rebecca TaubCMOSell648$335.24$217,235.52 1/24/2025Robert E WaltermireVPSell103$335.24$34,529.72 1/24/2025William John SiboldCEOSell1,584$335.24$531,020.16 1/17/2025Rebecca TaubCMOSell1,689$273.41$461,789.49 1/17/2025Robert E WaltermireVPSell442$273.41$120,847.22 1/17/2025Shannon T KelleyGeneral CounselSell277$273.41$75,734.57 12/3/2024Fred B CravesDirectorSell3,600$315.31$1,135,116.00 11/25/2024Fred B CravesDirectorSell3,400$350.30$1,191,020.00 11/1/2024Richard S LevyDirectorSell5,000$300.94$1,504,700.00 (Data available from 1/1/2013 forward) MDGL Insider Trading Activity - Frequently Asked Questions Who is on Madrigal Pharmaceuticals' Insider Roster? The list of insiders at Madrigal Pharmaceuticals includes Brian Joseph Lynch, Bros. Advisors Lp Baker, Carole Huntsman, Fred B Craves, James M Daly, Kenneth Bate, Paul A Friedman, Rebecca Taub, Remy Sukhija, Richard S Levy, Robert E Waltermire, Shannon T Kelley, and William John Sibold. Learn more on insiders at MDGL. What percentage of Madrigal Pharmaceuticals stock is owned by insiders? 21.50% of Madrigal Pharmaceuticals stock is owned by insiders. Learn more on MDGL's insider holdings. Which Madrigal Pharmaceuticals insiders have been buying company stock? The following insider purchased MDGL shares in the last 24 months: Bros. Advisors Lp Baker ($105,303,185.79). How much insider buying is happening at Madrigal Pharmaceuticals? Insiders have purchased a total of 391,750 MDGL shares in the last 24 months for a total of $105,303,185.79 bought. Which Madrigal Pharmaceuticals insiders have been selling company stock? The following insiders have sold MDGL shares in the last 24 months: Brian Joseph Lynch ($1,190,726.00), Carole Huntsman ($116,328.28), Fred B Craves ($7,113,594.32), James M Daly ($8,713,946.03), Kenneth Bate ($3,652,000.00), Paul A Friedman ($86,157,944.11), Rebecca Taub ($41,994,262.23), Richard S Levy ($4,336,980.00), Robert E Waltermire ($7,296,087.23), Shannon T Kelley ($555,358.81), and William John Sibold ($8,374,022.10). How much insider selling is happening at Madrigal Pharmaceuticals? Insiders have sold a total of 545,503 Madrigal Pharmaceuticals shares in the last 24 months for a total of $169,501,249.11 sold. Madrigal Pharmaceuticals Key ExecutivesDr. Rebecca A. Taub M.D. (Age 72)Founder, Chief Medical Officer, President of Research & Development and Director Compensation: $939.83kMr. Brian J. Lynch J.D. (Age 62)Senior VP & General Counsel Compensation: $763.75kMr. Alex G. Howarth (Age 55)Executive Officer Compensation: $757.26kMr. William J. Sibold (Age 58)CEO, President & Director 2 recent tradesMs. Mardi C. Dier (Age 60)CFO, Principal Financial Officer, Principal Accounting Officer & Senior VP Mr. Ronald FilippoChief Information OfficerMs. Tina E. VenturaChief Investor Relations OfficerDr. Kianoush Motesharei Ph.d. (Age 54)Senior Vice President of Business & Corporate Development Mr. Clint WallaceChief Human Resources OfficerMr. Edward ChiangSenior Vice President of Clinical & Technical Operations More Insider Trading Tools from MarketBeat Related Companies Biogen Insider Buying United Therapeutics Insider Buying Incyte Insider Buying Neurocrine Biosciences Insider Buying Exelixis Insider Buying BioMarin Pharmaceutical Insider Buying Exact Sciences Insider Buying Ionis Pharmaceuticals Insider Buying Halozyme Therapeutics Insider Buying Repligen Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles $100 Million Buyback in Upwork Stock Follows a Strong Quarter Insiders Sell These High-Quality Stocks: Why Investors Shouldn’tCoreWeave and Madrigal's Insider Trades Flash Bullish SignalsPalantir Insider Selling: Risk Signal or Normal Activity?Loop Industries Insiders Buy Stock, Signal Confidence in Outlook This page (NASDAQ:MDGL) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
